Biblio
2014
Terwijn, M., Zeijlemaker, W., Kelder, A., Rutten, A.P., Snel, A.N., Scholten, W.J., Pabst, T., Verhoef, G., Löwenberg, B., Zweegman, S., et al. (2014).
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia.Plos One
9, e107587.
2015
Berger, M.D., Branger, G., Klaeser, B., Taleghani, B.Mansouri, Novak, U., Banz, Y., Mueller, B.U., and Pabst, T. (2015).
Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.Hematol Oncol.
2016
Stettler, J., Novak, U., Baerlocher, G.M., Seipel, K., Taleghani, B.Mansouri, and Pabst, T. (2016).
Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.Leuk Lymphoma1-8.
2019
Moser, S., Bacher, U., Jeker, B., Taleghani, B.Mansouri, Betticher, D., Ruefer, A., Egger, T., Novak, U., and Pabst, T. (2019).
Autologous stem cell transfusions on multiple days in patients with multiple myeloma - does it matter?.Hematol Oncol.
]